Understanding the dopaminergic deficits in Parkinson's disease: insights into disease heterogeneity.
about
The relationships between mild cognitive impairment and phenotype in Parkinson's diseaseDoes anxiety cause freezing of gait in Parkinson's disease?Neurotensin inhibits both dopamine- and GABA-mediated inhibition of ventral tegmental area dopamine neuronsCognitive impairment in Parkinson's disease: the dual syndrome hypothesis.Review of recent advances in analytical techniques for the determination of neurotransmittersA new trend on biosensor for neurotransmitter choline/acetylcholine--an overview.Regional alterations of brain microstructure in Parkinson's disease using diffusion tensor imaging.Regional volume analysis of the Parkinson disease brain in early disease stage: gray matter, white matter, striatum, and thalamus.Parkinson's Disease in a Dish: What Patient Specific-Reprogrammed Somatic Cells Can Tell Us about Parkinson's Disease, If Anything?Discrimination and categorization of emotional facial expressions and faces in Parkinson's disease.A holistic analysis of relationships between executive function and memory in Parkinson's disease.Detecting dopaminergic neuronal degeneration using diffusion tensor imaging in a rotenone-induced rat model of Parkinson's disease: fractional anisotropy and mean diffusivity values.Anxiety-provoked gait changes are selectively dopa-responsive in Parkinson's disease.Exploring the Phenotype in Mild Cognitive Impairment to Aid the Prediction of Those at Risk of Transitioning to Parkinson Disease and Dementia With Lewy Bodies.The heterogeneity of cognitive symptoms in Parkinson's disease: a meta-analysis.Attentional set-shifting in Parkinson's disease patients with freezing of gait-acquisition and discrimination set learning deficits at the background?
P2860
Q33917203-188E0359-84EA-45B5-AED2-65D06E75A1E4Q34243678-B70FCF6C-C9D8-4433-B854-FC514DF16066Q36064795-79C2F88E-C369-4B8F-8DA9-7BF50EE616B0Q37364568-EA03CDCE-4758-4FBC-8A74-5695BD37805EQ37381103-03A408E6-09EA-45A7-8133-592BC66542F4Q38077094-196531CD-74B1-4D7C-9FD4-90E6161F720EQ41833538-CD5C4777-C8ED-4EC5-9791-864697973236Q42484117-D6A61276-3DFF-4225-83F2-489E4E0E7858Q42562656-823AC6CF-EA0C-4381-A680-8A01DF844D0CQ43773609-CACF9050-9E51-4087-892B-F1FD422396BCQ43846283-ADE2D152-6239-4506-89C3-E4A4E6707DBAQ47393581-A5A42BB5-E783-44C7-A44A-13FFFB75DC8FQ47711715-9D3DC129-5465-4FC1-8AE5-C2430D701265Q47717568-7787CB34-84DD-4A2B-A2A6-88008448B20FQ48483729-758CBA86-A0BA-4988-97F5-4A01C54D6FBDQ50629344-D31DA251-3BA0-464D-93EE-FBBB2F825D63
P2860
Understanding the dopaminergic deficits in Parkinson's disease: insights into disease heterogeneity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Understanding the dopaminergic ...... ts into disease heterogeneity.
@en
Understanding the dopaminergic ...... ts into disease heterogeneity.
@nl
type
label
Understanding the dopaminergic ...... ts into disease heterogeneity.
@en
Understanding the dopaminergic ...... ts into disease heterogeneity.
@nl
altLabel
Understanding the dopaminergic ...... hts into disease heterogeneity
@en
prefLabel
Understanding the dopaminergic ...... ts into disease heterogeneity.
@en
Understanding the dopaminergic ...... ts into disease heterogeneity.
@nl
P1476
Understanding the dopaminergic ...... ts into disease heterogeneity.
@en
P304
P356
10.1016/J.JOCN.2008.08.020
P577
2009-03-13T00:00:00Z